Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Bristol-Myers Squibb Company Add to portfolio

INX:BMY, Feb 28, 11:31 UTC

Latest INX:BMY News

Filter your feed

Apply Filter

Tuesday, February 25


News

Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019

BMY

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.67%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.

Read Full Details

Topics:
  • Business
  • Financial
News

Feb 25, 2020 - Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019

BMY

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.65%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.

Read Full Details

Topics:
  • Business
  • Financial
News

Feb 25, 2020 - Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019

BMY

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.61%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.

Read Full Details

Topics:
  • Business
  • Financial
News

Feb 25, 2020 - Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019

BMY

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.61%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.

Read Full Details

Topics:
  • Business
  • Financial
News

Feb 24, 2020 - Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019

BMY

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.61%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.

Read Full Details

Topics:
  • Business
  • Financial

Monday, February 24


News

Feb 24, 2020 - Bristol-Myers Squibb Company (BMY) Files 10-K for the Fiscal Year Ended on December 31, 2019

BMY

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The dividend yield of Bristol-Myers Squibb Company stocks is 2.61%. Bristol-Myers Squibb Company had annual average EBITDA growth of 18.40% over the past five years. For the last quarter Bristol-Myers Squibb Company reported a revenue of $7.9 billion, compared with the revenue of $6 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 billion, an increase of 15.9% from last year. For the complete 30-year financial data, please go here.. For the last five years Bristol-Myers Squibb Company had an average revenue growth rate of 10.5% a year.

Read Full Details

Topics:
  • Business
  • Financial
News

Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy?

BMY

Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy? ZacksFebruary 24, 2020, 4:45 PM UTC. Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Headquartered in New York, Bristol-Myers Squibb (BMY) is a Medical stock that has seen a price change of 2.24% so far this year.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

BMY

Bristol-Myers Squibb also AdvancesBMS-986288 into a Separate Phase 1/2a Clinical Trial. SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that its partner, Bristol-Myers Squibb, has initiated a randomized Phase 2 cohort expansion in its ongoing first-in-human Phase 1/2a trial of the anti-CTLA-4 Probody BMS-986249 alone and in combination with Opdivo® (nivolumab). BMS-986249 is a peptide masked version of the anti-CTLA-4 antibody Yervoy® (ipilimumab). We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel Probody Platform technology; CytomX and its partners have five product candidates utilizing CytomX’s Probody platform in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomX’s clinical trials will not be successful; CytomX’s dependence on the success of CX-072, CX-2009, CX-2029 and BMS-986249; CytomX’s reliance on third parties for the manufacture of the company’s product candidates; and possible regulatory developments in the United States and foreign countries.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Saturday, February 22


News

A Big Month Ahead for the FDA and Bristol-Myers Squibb

BMY CELG

It's been a few months since Bristol-Myers Squibb(NYSE: BMY) completed its $74 billion purchase of Celgene, but investors still aren't sure if a couple of key assets that spurred the transaction will ever generate sales. Image source: Getty Images. If you're considering Bristol-Myers Squibb stock, it's probably best to see how the following three decisions play out first. During trials supporting ozanimod's application, patients treated with the drug experienced significantly less disease progression than those given standard care. Solid trial results mean there's a very good chance the FDA will grant approval to ozanimod. Earlier this year, Bristol-Myers withdrew an application to treat newly diagnosed lung cancer patients with its cancer immunotherapy combination, Opdivo plus Yervoy. Even though the important first-line lung cancer indication is probably out of reach, the pair of checkpoint inhibitors generated a whopping $8.1 billion in combined sales last year.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial

Friday, February 21


News

Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Earnest Partners LLC – Enterprise Echo

BMY

Earnest Partners LLC grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 45.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. Citigroup upgraded Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 price target on the stock in a report on Monday, January 6th. The company has a market cap of $107.06 billion, a P/E ratio of 29.76, a P/E/G ratio of 1.26 and a beta of 0.76. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $68.34.

Read Full Details

Topics:
  • Business
  • Health
  • Financial